Hot Products

Morachalcone A
Catalog No: CFN97241

Morachalcone A displays significant tyrosinase inhibitory activity (IC50, 0.013 uM); it also exerts strong pancreatic lipase inhibition with IC 50 value of 6.2 uM. Morachalcone A exhibits neuroprotective effects on HT22-immortalized hippocampal cells against glutamate-induced oxidative stress, with EC50 values of 35.5±2.1 uM. It exhibits potent inhibitory activity on nitric oxide production in RAW264.7 LPS-activated mouse macrophage cells with IC50 value of 16.4 microM.

Moracin C
Catalog No: CFN97178

Moracin C and D, new phytoalexins from diseased mulberry, are antifungal compounds. Moracin C has potent antibacterial activity, it can inhibit FabI and fatty acid synthesis, it inhibit S. aureus FabI with IC(50) of 83.8 uM. Moracin C has anti-inflammatory effect, it can effectively reduce lipopolysaccharide (LPS) stimulated up-regulation of mRNA and protein expression of iNOS, COX-2, and serval pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α).Moracin may be protective influence in tumor promotion, utilization of Moracin may open a new avenue in the treatment of tumerigenesis.

Moracin D
Catalog No: CFN97179

Moracin C and moracin D, new phytoalexins from diseased mulberry, are antifungal compounds. Moracin may be protective influence in tumor promotion, utilization of Moracin may open a new avenue in the treatment of tumerigenesis.

Moracin M
Catalog No: CFN92327

Moracin M is a phytoalexin. Moracin M inhibits PDE4D2, PDE4B2, PDE5A1, and PDE9A2 with the IC(50) values of 2.9, 4.5, >40, and >100 μM, respectively.

Moracin O
Catalog No: CFN96102

Moracin O shows significant neuroprotective, and analgesic activities, it also has a strong protective influence against doxorubicin-induced cardiomyopathy in H9c2 cells with the EC50 value of 4.5 ± 1.3 uM. Moracin O exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia.

Moracin P
Catalog No: CFN92324

Moracin P exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia. Moracin P might protect neuronal cell death against the oxidative stress induced by oxygen-glucose deprivation(OGD), can enhance cell viability in dose-dependent manner against OGD-induced cell death in neuroblastoma SH-SY5Y cells.

Moracin T
Catalog No: CFN92326

Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte infiltration, hyperplasia and cell proliferation; moracin treatment furthermore can significantly suppress the elevation in 4-HNE level and elevate expression of c-fos, c-myc and cycloxygenase-2 (COX-2) in normal epidermis induced by double application of TPA; the moracin may be protective influence in tumor promotion, utilization of Moracin may open a new avenue in the treatment of tumerigenesis.

Morellic acid
Catalog No: CFN92093

Morellic acid has anti-cancer activity, it strongly inhibited the migration of HUVEC at a low concentration of 0.5 μM in HUVEC cell migration assay in vitro. Morellic acid also has antiangiogenic activity.

Morin
Catalog No: CFN99929

Morin, a α-glucosidase inhibitor with an IC50 value of (4.48 ± 0.04) uM, it also exhibits inhibition in the generation of advanced glycation end products which was related to the long term complications of diabetes. Morin has anti-inflammatory and anti-oxidative effects by activating Nrf2 signal pathways and inhibiting NF-κB activation. it can be used to prevent bladder cancer, it prevents MMP-9 expression via the inhibition of transcription factors AP-1, Sp-1, and NF-κB.

Morindin
Catalog No: CFN70420

Reference standards.